reports
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 ...
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026 CONSHOHOCKEN, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2025 financial results on Thursday, Feb. 19, 2026, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results. The live webcast may be accessed at the Inv...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under N...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on January 15, 2026 to 40 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in ac...
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nas...
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted an equity award on January 15, 2026 to Rita Thakkar, the company’s new Chief Accounting Officer, as an equity inducement award under the terms of Madrigal’s 2025 Inducement Plan. The equity award was approved by Madrigal’s Board of Dire...
Madrigal Expands its MASH Pipeline with Exclusive Global License Agree...
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra® (resmetirom) for potential additive therapeutic benefit in MASHMadrigal to present at the 44th Annual J.P. Morgan Healthcare Conference at 1:30 p.m. PST (4:30 p.m. EST) on Monday, January 12, 2026 CONSHOHOCKEN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDG...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under N...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on December 15, 2025 to 4 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in ac...
Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Hea...
Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on Monday, January 12, 2026 at 1:30pm PST. The presentation will be broadcast live and can be accessed or by visiting Madrigal’s Investor Relations Events and Presentations . A replay of the webcast will be available after the event. About MadrigalMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biophar...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under N...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on December 1, 2025 to 24 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in ac...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Back to Near-Term Bullish on SPX and QQQ We downgraded our near-term outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) to neutral last week (11/19/25 Compass), after being bullish since our 4/22/25 Compass, while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are right back to being near-term bullish as long as these support levels continue to hold. Just know that SPX could see...
WAT WATERS CORPORATION
VCYT VERACYTE INC
TMO THERMO FISHER SCIENTIFIC INC.
RGEN REPLIGEN CORPORATION
PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC.
IDXX IDEXX LABORATORIES INC.
HALO HALOZYME THERAPEUTICS INC.
EXEL EXELIXIS INC.
CRL CHARLES RIVER LABORATORIES INTERNATIONAL INC.
BRKR BRUKER CORPORATION
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ANGO ANGIODYNAMICS INC.
BIO BIO-RAD LABORATORIES INC. CLASS A
IONS IONIS PHARMACEUTICALS INC.
PKI PERKINELMER INC.
UTHR UNITED THERAPEUTICS CORPORATION
FLGT FULGENT GENETICS
MDGL MADRIGAL PHARMACEUTICALS
CELC CELCUITY
DNLI DENALI THERAPEUTICS INC
STE STERIS PLC
CSTL CASTLE BIOSCIENCES
TXG 10X GENOMICS INC CLASS A
VIR VIR BIOTECHNOLOGY
RPRX ROYALTY PHARMA PLC CLASS A
ADPT ADAPTIVE BIOTECHNOLOGIES
PRPO PRECIPIO INC.
Madrigal Pharmaceuticals Inc: 1 director
A director at Madrigal Pharmaceuticals Inc sold 1,064 shares at 554.905USD and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under N...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on November 15, 2025 to three new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee i...
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Inv...
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences: Jefferies Global Healthcare Conference in LondonThursday, Nov. 20, 2025 at 8:30 A.M. GMT (3:30 A.M. ET)The presentation will be webcast live and may be accessed . 8th Annual Evercore Healthcare ConferenceTuesday, Dec. 2, 2025 at 4:15 P.M. ETThe presentation will be webcast live and may be accessed...
Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Signi...
Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis Rezdiffra® treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients with compensated MASH cirrhosis Rezdiffra also improved disease-specific quality of life measures in patients with and without cirrhosis, with sustained effect through two years of treatmentNew analysis examining effects of Rezdiffra treatment interruption u...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under N...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on November 1, 2025 to 18 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in ac...
Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results ...
Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates Third-quarter 2025 Rezdiffra™ (resmetirom) net sales of $287.3 millionAs of September 30, 2025, more than 29,500 patients on Rezdiffra Closed global licensing agreement with CSPC Pharma to add oral GLP-1 to pipeline New Orange Book listed patent for Rezdiffra providing protection into 2045 Launched Rezdiffra in Germany following European Commission approval Reports cash, cash equivalents, restricted cash and marketable securities of $1.1 billion as of Sept. 30, 2025Company to host conference...
Madrigal to Present New Data from the Company’s MASH Program at AASLD’...
Madrigal to Present New Data from the Company’s MASH Program at AASLD’s The Liver Meeting 2025 Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of RezdiffraPoster of distinction examines the impact of Rezdiffra interruption on patients, underscoring the need for continued treatment to prevent disease progressionFurther poster presentations examine early real-world experience with Rezdiffra and the clinical burden of MASH CONSHOHOCKEN, Pa., Oct. 28, 2025 (GLOBE NEWS...
Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Resul...
Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025 CONSHOHOCKEN, Pa., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its third-quarter 2025 financial results on Tuesday, Nov. 4, 2025, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to ...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under N...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on October 15, 2025 to 19 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in ...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Downgrading Financials to Underweight We remain bullish since our 4/22/25 Compass, and we will maintain our bullish outlook as long as market dynamics remain healthy and the S&P 500 (SPX) is above 6028-6059. We would need to see a break below 6569 in order to have confidence that a consolidation period has finally begun. For now, we continue to expect support to show up at the 4-month uptrend, which generally coincides with the 20-day MA. Short-term supports to buy include 6640 (the 20-day MA),...
TECH BIO-TECHNE CORPORATION
RGEN REPLIGEN CORPORATION
REGN REGENERON PHARMACEUTICALS INC.
GILD GILEAD SCIENCES INC.
EXEL EXELIXIS INC.
EXAS EXACT SCIENCES CORPORATION
ENS ENERSYS
BIIB BIOGEN INC.
BGNE BEIGENE LTD. SPONSORED ADR
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ALNY ALNYLAM PHARMACEUTICALS INC
IONS IONIS PHARMACEUTICALS INC.
UTHR UNITED THERAPEUTICS CORPORATION
MDGL MADRIGAL PHARMACEUTICALS
RPRX ROYALTY PHARMA PLC CLASS A
ADPT ADAPTIVE BIOTECHNOLOGIES
QS QUANTUMSCAPE
ENVX ENOVIX CORP
FLNC FLUENCE ENERGY INC
SLDP SOLID POWER INC
MVST MICROVAST HLDGS INC
AMPX AMPRIUS TECHNOLOGIES INC
SES SES AI CORPORATION
ABAT AMERICAN BATTERY TECHNOLOGY COMPANY
TE ALUSSA ENERGY ACQUISITION CORP
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under N...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on October 1, 2025 to 27 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in acc...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under N...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on September 15, 2025 to 76 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.